C4 Therapeutics, Inc. (CCCC)
3.74
-0.05
(-1.32%)
USD |
NASDAQ |
Sep 03, 16:00
3.76
+0.02
(+0.53%)
After-Hours: 20:00
C4 Therapeutics Research and Development Expense (TTM) : 100.05M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 100.05M |
| March 31, 2026 | 101.77M |
| December 31, 2025 | 104.24M |
| September 30, 2025 | 111.77M |
| June 30, 2025 | 117.62M |
| March 31, 2025 | 115.18M |
| December 31, 2024 | 110.64M |
| September 30, 2024 | 108.52M |
| June 30, 2024 | 105.02M |
| March 31, 2024 | 111.20M |
| December 31, 2023 | 117.71M |
| September 30, 2023 | 117.97M |
| June 30, 2023 | 119.28M |
| Date | Value |
|---|---|
| March 31, 2023 | 120.68M |
| December 31, 2022 | 117.84M |
| September 30, 2022 | 113.74M |
| June 30, 2022 | 108.38M |
| March 31, 2022 | 99.95M |
| December 31, 2021 | 93.83M |
| September 30, 2021 | 87.34M |
| June 30, 2021 | 86.56M |
| March 31, 2021 | 81.00M |
| December 31, 2020 | 76.82M |
| September 30, 2020 | 72.44M |
| June 30, 2020 | 61.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Beam Therapeutics, Inc. | 408.66M |
| Rallybio Corp. | 7.384M |
| Q32 Bio, Inc. | 14.35M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |